N-(2-(2-酞酰亚胺基乙氧基)乙酰基)-L-丙氨酰-D-谷氨酸 | 75513-70-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2-(2-酞酰亚胺基乙氧基)乙酰基)-L-丙氨酰-D-谷氨酸
• 英文名称: 5-(3-Hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide
• 英文别名: 4-[(E)-[hydroxymethyl(methyl)amino]diazenyl]-1H-imidazole-5-carboxamide
• CAS: 75513-70-1
• 化学式: C₆H₁₀N₆O₂
• 分子量: 198.18
• InChiKey: UGVTYCQVZPDYRZ-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS
  申请人：Gokaraju Ganga Raju

  公开号：US20100068178A1

  公开（公告）日：2010-03-18

  The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.

  本发明公开了一般式(I)和式(II)的三氮烯类似物，其互变异构体、立体异构体、多晶形态、水合物、溶剂合物及其在转移性恶性黑色素瘤和其他癌症，包括但不限于淋巴瘤、肉瘤、癌瘤和胶质瘤中的药用可接受盐。该发明还公开了制备上述式(I)和式(II)的三氮烯类似物以及其药用可接受组合物的方法。
• ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS
  申请人：GOKARAJU Ganga Raju

  公开号：US20100272678A1

  公开（公告）日：2010-10-28

  Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R 1 , R 2 , R 3 , R 6 , and R 7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

  硒吡嗪三唑类似物，它们的组成物，互变异构体，立体异构体，多晶形态，水合物，溶剂合物，以及其药用可接受的盐和混合物对于治疗转移性恶性黑色素瘤和其他癌症是有用的。硒吡嗪三唑类似物具有一般式(I)或(II)：其中取代基R1、R2、R3、R6和R7如规范中所述。这些化合物可用于治疗的其他癌症包括但不限于恶性黑色素瘤、白血病、淋巴瘤（霍奇金病和非霍奇金病）、肉瘤（尤因肉瘤）、脑肿瘤、中枢神经系统（CNS）转移、胶质瘤、癌症如乳腺癌、前列腺癌、肺癌（小细胞和非小细胞）、结肠癌、胰腺癌、头颈癌和口咽鳞状细胞癌。
• Prodrugs Activated by Reduction in the Cytosol
  申请人：YALE UNIVERSITY

  公开号：US20200384002A1

  公开（公告）日：2020-12-10

  The present invention provides prodrug modifications for chemotherapeutic drugs that allow activation in the cytosol.
• US8143237B2
  申请人：——

  公开号：US8143237B2

  公开（公告）日：2012-03-27
• US8258119B2
  申请人：——

  公开号：US8258119B2

  公开（公告）日：2012-09-04